Cory Iverson

769 total citations
15 papers, 599 citations indexed

About

Cory Iverson is a scholar working on Molecular Biology, Oncology and Nephrology. According to data from OpenAlex, Cory Iverson has authored 15 papers receiving a total of 599 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 6 papers in Oncology and 3 papers in Nephrology. Recurrent topics in Cory Iverson's work include Melanoma and MAPK Pathways (5 papers), Gout, Hyperuricemia, Uric Acid (3 papers) and PI3K/AKT/mTOR signaling in cancer (3 papers). Cory Iverson is often cited by papers focused on Melanoma and MAPK Pathways (5 papers), Gout, Hyperuricemia, Uric Acid (3 papers) and PI3K/AKT/mTOR signaling in cancer (3 papers). Cory Iverson collaborates with scholars based in United States, New Zealand and France. Cory Iverson's co-authors include Jeffrey N. Miner, Li‐Tain Yeh, Sofia Aronova, Stephen R. Fairclough, John R. Yates, Stephanie Chu, Ted Powers, J. Michael McCaffery, Barry Quart and Karen P. Wedaman and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Cory Iverson

13 papers receiving 586 citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Cory Iverson	394	122	97	85	58	15	599
Yitao Ou	300 0.8×	57 0.5×	28 0.3×	40 0.5×	71 1.2×	19	603
Virginie Poindessous	484 1.2×	38 0.3×	61 0.6×	282 3.3×	44 0.8×	32	837
Graziella Malaponte	241 0.6×	30 0.2×	45 0.5×	125 1.5×	56 1.0×	10	481
Francesca Conserva	449 1.1×	120 1.0×	23 0.2×	115 1.4×	55 0.9×	26	774
Yuekun Zhu	812 2.1×	35 0.3×	93 1.0×	165 1.9×	90 1.6×	29	1.1k
Marilena Crescimanno	233 0.6×	34 0.3×	25 0.3×	126 1.5×	39 0.7×	16	483
Xisha Chen	544 1.4×	33 0.3×	37 0.4×	217 2.6×	29 0.5×	21	800
Wenjuan Mei	257 0.7×	55 0.5×	30 0.3×	81 1.0×	33 0.6×	35	466
Zhirong Jia	316 0.8×	26 0.2×	37 0.4×	89 1.0×	61 1.1×	23	632
Suresh Guruswamy	411 1.0×	20 0.2×	26 0.3×	140 1.6×	64 1.1×	16	608

Countries citing papers authored by Cory Iverson

Since Specialization

Citations

This map shows the geographic impact of Cory Iverson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cory Iverson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cory Iverson more than expected).

Fields of papers citing papers by Cory Iverson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cory Iverson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cory Iverson. The network helps show where Cory Iverson may publish in the future.

Co-authorship network of co-authors of Cory Iverson

This figure shows the co-authorship network connecting the top 25 collaborators of Cory Iverson. A scholar is included among the top collaborators of Cory Iverson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cory Iverson. Cory Iverson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Cramer, Elizabeth, Cory Iverson, Korey A. Kennelty, et al.. (2025). Listening to the note: clinician perspectives on ambient artificial intelligence scribes in medical documentation. Journal of the American Medical Informatics Association. 33(2). 255–262. 1 indexed citations

Gordon, Darren M., et al.. (2025). Assessment of Differences in Colorectal Cancer Outcomes by Geographic Region for Black Patients in the United States. Journal of Racial and Ethnic Health Disparities.

McKinney, Cushla, Tanya J. Major, Lisa K. Stamp, et al.. (2018). The relationship between ferritin and urate levels and risk of gout. Arthritis Research & Therapy. 20(1). 179–179. 31 indexed citations

Iverson, Cory, Sha Liu, Scott Baumgartner, et al.. (2018). Omega-3-carboxylic acids provide efficacious anti-inflammatory activity in models of crystal-mediated inflammation. Scientific Reports. 8(1). 1217–1217. 24 indexed citations

Miner, Jeffrey N., Philip K. Tan, David Hyndman, et al.. (2016). Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney. Arthritis Research & Therapy. 18(1). 214–214. 107 indexed citations

Merriman, Tony R., et al.. (2016). AB0830 Iron Metabolism: Association of Ferritin with Serum Urate and Gout. Annals of the Rheumatic Diseases. 75. 1187–1187.

Adjei, Alex A., Donald Richards, Anthony B. El-Khoueiry, et al.. (2015). A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer. Clinical Cancer Research. 22(10). 2368–2376. 16 indexed citations

Weekes, Colin D., Daniel D. Von Hoff, Alex A. Adjei, et al.. (2013). Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer. Clinical Cancer Research. 19(5). 1232–1243. 46 indexed citations

Gore, Lia, Kriste A. Lewis, Daniel D. Von Hoff, et al.. (2011). Safety, pharmacokinetics, and pharmacodynamics results from a phase I trial of BAY 86-9766 (RDEA119), a MEK inhibitor, in patients with advanced cancer.. Journal of Clinical Oncology. 29(15_suppl). 3007–3007. 10 indexed citations

10.

Adjei, Alex A., Donald Richards, Anthony B. El-Khoueiry, et al.. (2011). Abstract A88: Safety, pharmacokinetic, and pharmacodynamic results of BAY 86–9766, an oral MEK inhibitor, in combination with sorafenib, an oral multikinase inhibitor, in advanced cancer patients.. Molecular Cancer Therapeutics. 10(11_Supplement). A88–A88. 1 indexed citations

11.

Weekes, Colin D., Daniel D. Von Hoff, Alex A. Adjei, et al.. (2010). 368 A multi-center Phase 1, dose-escalation trial to determine the safety and pharmacokinetics/pharmacodynamics of BAY 86-9766 (RDEA119), a MEK inhibitor, in advanced cancer patients. European Journal of Cancer Supplements. 8(7). 116–116. 2 indexed citations

12.

Iverson, Cory, Gary Larson, Chon Lai, et al.. (2009). RDEA119/BAY 869766: A Potent, Selective, Allosteric Inhibitor of MEK1/2 for the Treatment of Cancer. Cancer Research. 69(17). 6839–6847. 153 indexed citations

13.

Miner, Jeffrey H., Cory Iverson, Robert Hamatake, et al.. (2008). 577 POSTER Selective MEK Inhibitor RDEA119 exhibits efficacy in orthotopic hepatoma models and cytostatic potential in multiple cell based models of cancer. European Journal of Cancer Supplements. 6(12). 181–181. 2 indexed citations

14.

Hamatake, Robert, Li‐Tain Yeh, Hong Kim, et al.. (2007). RDEA119: A potent and highly selective MEK inhibitor for the treatment of cancer. Molecular Cancer Therapeutics. 6. 3 indexed citations

15.

Anderson, Scott, J. Michael McCaffery, John R. Yates, et al.. (2004). TOR Complex 1 Includes a Novel Component, Tco89p (YPL180w), and Cooperates with Ssd1p to Maintain Cellular Integrity in Saccharomyces cerevisiae. Journal of Biological Chemistry. 279(15). 14752–14762. 203 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact